Chugai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the year ended December 31, 2022. For the period, the company expects revenues of ¥1,150,000 million, Core operating profit of ¥440,000 million, Core net income of ¥312,500 million and Core earnings per share of ¥190.00.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,787 JPY | -0.52% | +0.48% | -10.39% |
May. 23 | Tech stocks lift Japan's Nikkei on boost from Nvidia's robust outlook | RE |
May. 14 | Japan's Nikkei drifts sideways as more earnings, US CPI awaited | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.39% | 50.72B | |
+42.60% | 748B | |
+34.01% | 598B | |
-5.74% | 356B | |
+17.79% | 325B | |
+3.37% | 283B | |
+17.13% | 245B | |
+9.47% | 211B | |
-3.80% | 209B | |
+1.81% | 166B |
- Stock Market
- Equities
- 4519 Stock
- News Chugai Pharmaceutical Co., Ltd
- Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2022